Archive

Neovasc Comments on EuroIntervention Article

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - April 19, 2021 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with...

Read More

NEOVASC PROVIDES TIARA TA UPDATE

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - April 16, 2021 - Neovasc Inc.("Neovasc" or the "Company") (NASDAQ,TSX: NVCN), today announced that the Tiara Transapical system (Tiara TA) will be unable to receive a European CE mark under the current Medical Device Directive regulations (MDD) ending on...

Read More

Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results

  VANCOUVER and MINNEAPOLIS – March 11, 2021 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020.  Fourth Quarter Highlights  Generated revenue of $514,000 in the quarter and $1.96 million for the...

Read More

Neovasc Comments on Clinical Cardiology Journal Publication

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - March 02, 2021 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study. The article, authored...

Read More

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

Vancouver, British Columbia and Minneapolis, Minnesota – Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum market value requirement set...

Read More